• Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

  • 2024/10/25
  • 再生時間： 46 分
  • ポッドキャスト

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPROTACmBC24).
    続きを読む 一部表示

あらすじ・解説

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPROTACmBC24).
続きを読む 一部表示

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancerに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。